Anavex Life Sciences Corp (AVXL)

[Investor2014]

“Do you believe the 99.6% failure rate for Alzheimer’s trials doesn’t apply to Anavex because A2-73 is targeting Sigma 1 and not A-beta and Plaques?”

In a sense we might need to reset the counter from an ‘A-beta plaque’ one to a new one counting alternative approaches, which includes Donepezil and starts at let’s say 60% failure rate (I don’t know exactly how many non-A-beta drugs have made it into a registration trial).

Dr. Perry reckoned that we are nearer 99.8% failure on the plaque attempts with recent failures by Lundbeck, Biogen mand others.

Perhaps A2-73 has a say 50% chance of reducing the failure rate counter in the non-plaque class.

The other points you raise from the now vTv drug’s past attempts could be valid considerations.

Interesting and exciting what happens over the next 1 to 2 years.